Distinct roles for ROCK1 and ROCK2 in the regulation of cell detachment

Cell Death and Disease

Volumn 4, Issue 2, 2013, Pages

  Shi, Jianjian ^a   Wu, Xiangbing ^a   Surma, Michelle ^a   Vemula, Sasidhar ^a   Zhang, Lumin ^a   Yang, Yu ^a   Kapur, Reuben ^a   Wei, Lei ^a,b  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b INDIANA UNIVERSITY   (United States)

Author keywords

Actin cytoskeleton remodeling; Apoptosis; Detachment; Isoform function; Rho kinase

Indexed keywords

4 (1 AMINOETHYL) N (4 PYRIDYL)CYCLOHEXANECARBOXAMIDE; ACTIN; BLEBBISTATIN; COFILIN; CYTOCHALASIN D; DOXORUBICIN; MYOSIN ADENOSINE TRIPHOSPHATASE; MYOSIN LIGHT CHAIN 2; RHO KINASE; RHO KINASE 1; RHO KINASE 2; UNCLASSIFIED DRUG;

ACTIN FILAMENT; ANIMAL CELL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CELL ADHESION; CELL DETACHMENT; CELL MEMBRANE; CELL STRESS; CYTOTOXICITY; EMBRYO; ENZYME ACTIVITY; FIBROBLAST; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; PROTEIN POLYMERIZATION; PROTEIN STABILITY; STRESS FIBER;

ACTIN CYTOSKELETON; ACTINS; AMIDES; ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; CARDIAC MYOSINS; CASPASES; CELL LINE; CELL SHAPE; CELL SURVIVAL; COFILIN 1; CYTOCHALASIN D; DOXORUBICIN; MICE; MICE, KNOCKOUT; MYOSIN LIGHT CHAINS; PHOSPHORYLATION; PYRIDINES; RHO-ASSOCIATED KINASES;

MUS;

EID: 84875994759     PISSN: None     EISSN: 20414889     Source Type: Journal    
DOI: 10.1038/cddis.2013.10     Document Type: Article

References (59)

1. Matsui T, Amano M, Yamamoto T, Chihara K, Nakafuku M, Ito M et al. Rho-associated kinase, a novel serine/threonine kinase, as a putative target for small gtp binding protein rho. EMBO J 1996; 15: 2208-2216.
2. Ishizaki T, Maekawa M, Fujisawa K, Okawa K, Iwamatsu A, Fujita A et al. The small gtpbinding protein rho binds to and activates a 160 kda ser/thr protein kinase homologous to myotonic dystrophy kinase. EMBO J 1996; 15: 1885-1893.
3. Nakagawa O, Fujisawa K, Ishizaki T, Saito Y, Nakao K, Narumiya S. Rock-i and rock-ii, two isoforms of rho-associated coiled-coil forming protein serine/threonine kinase in mice. FEBS Lett 1996; 392: 189-193.
4. Leung T, Chen XQ, Manser E, Lim L. The p160 rhoa-binding kinase rok alpha is a member of a kinase family and is involved in the reorganization of the cytoskeleton. Mol Cell Biol 1996; 16: 5313-5327.
5. Amano M, Ito M, Kimura K, Fukata Y, Chihara K, Nakano T et al. Phosphorylation and activation of myosin by rho-associated kinase (rho-kinase). J Biol Chem 1996; 271: 20246-20249.
6. Kimura K, Ito M, Amano M, Chihara K, Fukata Y, Nakafuku M et al. Regulation of myosin phosphatase by rho and rho-associated kinase (rho-kinase). Science 1996; 273: 245-248.
7. Maekawa M, Ishizaki T, Boku S, Watanabe N, Fujita A, Iwamatsu A et al. Signaling from rho to the actin cytoskeleton through protein kinases rock and lim-kinase. Science 1999; 285: 895-898.
8. Ohashi K, Nagata K, Maekawa M, Ishizaki T, Narumiya S, Mizuno K. Rho-associated kinase rock activates lim-kinase 1 by phosphorylation at threonine 508 within the activation loop. J Biol Chem 2000; 275: 3577-3582.
9. Hahmann C, Schroeter T. Rho-kinase inhibitors as therapeutics: From pan inhibition to isoform selectivity. Cell Mol Life Sci 2010; 67: 171-177.
10. Loirand G, Pacaud P. The role of rho protein signaling in hypertension. Nat Rev Cardiol 2010; 7: 637-647.
11. Miyamoto S, Del Re DP, Xiang SY, Zhao X, Florholmen G, Brown JH. Revisited and revised: Is rhoa always a villain in cardiac pathophysiology? J Cardiovasc Transl Res 2010; 3: 330-343.
12. Nunes KP, Rigsby CS, Webb RC. Rhoa/rho-kinase and vascular diseases: what is the link? Cell Mol Life Sci 2010; 67: 3823-3836.
13. Dong M, Yan BP, Liao JK, Lam YY, Yip GW, Yu CM. Rho-kinase inhibition: a novel therapeutic target for the treatment of cardiovascular diseases. Drug Discov Today 2010; 15: 622-629.
14. Amano M, Nakayama M, Kaibuchi K. Rho-kinase/rock: A key regulator of the cytoskeleton and cell polarity. Cytoskeleton (Hoboken) 2010; 67: 545-554.
15. Surma M, Wei L, Shi J. Rho kinase as a therapeutic target in cardiovascular disease. Future Cardiol 2011; 7: 657-671.
16. Olson MF. Applications for rock kinase inhibition. Curr Opin Cell Biol 2008; 20: 242-248.
17. Uehata M, Ishizaki T, Satoh H, Ono T, Kawahara T, Morishita T et al. Calcium sensitization of smooth muscle mediated by a rho-associated protein kinase in hypertension. Nature 1997; 389: 990-994.
18. Asano T, Ikegaki I, Satoh S, Suzuki Y, Shibuya M, Takayasu M et al. Mechanism of action of a novel antivasospasm drug, ha1077. J Pharmacol Exp Ther 1987; 241: 1033-1040.
19. Davies SP, Reddy H, Caivano M, Cohen P. Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J 2000; 351: 95-105.
20. Bain J, Plater L, Elliott M, Shpiro N, Hastie CJ, McLauchlan H et al. The selectivity of protein kinase inhibitors: a further update. Biochem J 2007; 408: 297-315.
21. Shi J, Zhang L, Wei L. Rho-kinase in development and heart failure: insights from genetic models. Pediatr Cardiol 2011; 32: 297-304.
22. Zhang YM, Bo J, Taffet GE, Chang J, Shi J, Reddy AK et al. Targeted deletion of rock1 protects the heart against pressure overload by inhibiting reactive fibrosis. Faseb J 2006; 20: 916-925.
23. Di Marco A, Gaetani M, Scarpinato B. Adriamycin (nsc-123,127): a new antibiotic with antitumor activity. Cancer Chemother Rep 1969; 53: 33-37.
24. Shi J, Zhang L, Zhang YW, Surma M, Payne RM, Wei L. Down-regulation of doxorubicininduced myocardial apoptosis accompanies postnatal heart maturation. Am J Physiol Heart Circ Physiol 2012; 302: H1603-H1613.
25. Zhang YW, Shi J, Li YJ, Wei L. Cardiomyocyte death in doxorubicin-induced cardiotoxicity. Arch Immunol Ther Exp (Warsz) 2009; 57: 435-445.
26. Sawyer DB, Peng X, Chen B, Pentassuglia L, Lim CC. Mechanisms of anthracycline cardiac injury: can we identify strategies for cardioprotection? Prog Cardiovasc Dis 2010; 53: 105-113.
27. Feng Z, Chen B, Tang SC, Liao K, Chen WN, Chan V. Effect of cytoskeleton inhibitors on deadhesion kinetics of hepg2 cells on biomimetic surface. Colloids Surf B Biointerfaces 2010; 75: 67-74.
28. Colombo R, Dalle Donne I, Milzani A. Metal ions modulate the effect of doxorubicin on actin assembly. Cancer Biochem Biophys 1990; 11: 217-226.
29. Mills JC, Stone NL, Pittman RN. Extranuclear apoptosis. The role of the cytoplasm in the execution phase. J Cell Biol 1999; 146: 703-708.
30. Vicente-Manzanares M, Ma X, Adelstein RS, Horwitz AR. Non-muscle myosin ii takes centre stage in cell adhesion and migration. Nat Rev Mol Cell Biol 2009; 10: 778-790.
31. Szczepanowska J, Korn ED, Brzeska H. Activation of myosin in hela cells causes redistribution of focal adhesions and f-actin from cell center to cell periphery. Cell Motil Cytoskeleton 2006; 63: 356-374.
32. Zagorska A, Deak M, Campbell DG, Banerjee S, Hirano M, Aizawa S et al. New roles for the lkb1-nuak pathway in controlling myosin phosphatase complexes and cell adhesion. Sci Signaling 2010; 3: ra25.
33. Sebbagh M, Renvoize C, Hamelin J, Riche N, Bertoglio J, Breard J. Caspase-3-mediated cleavage of rock i induces mlc phosphorylation and apoptotic membrane blebbing. Nat Cell Biol 2001; 3: 346-352.
34. Coleman ML, Sahai EA, Yeo M, Bosch M, Dewar A, Olson MF. Membrane blebbing during apoptosis results from caspase-mediated activation of Rock I. Nat Cell Biol 2001; 3: 339-345.
35. Frisch SM, Screaton RA. Anoikis mechanisms. Curr Opin Cell Biol 2001; 13: 555-562.
36. Kovacs M, Toth J, Hetenyi C, Malnasi-Csizmadia A, Sellers Jr. Mechanism of blebbistatin inhibition of myosin ii. J Biol Chem 2004; 279: 35557-35563.
37. May JA, Ratan H, Glenn JR, Losche W, Spangenberg P, Heptinstall S. Gpiib-iiia antagonists cause rapid disaggregation of platelets pre-treated with cytochalasin d. Evidence that the stability of platelet aggregates depends on normal cytoskeletal assembly. Platelets 1998; 9: 227-232.
38. Katoh K, Kano Y, Noda Y. Rho-associated kinase-dependent contraction of stress fibres and the organization of focal adhesions. J R Soc Interface 2011; 8: 305-311.
39. Yoneda A, Multhaupt HA, Couchman Jr. The rho kinases i and ii regulate different aspects of myosin ii activity. J Cell Biol 2005; 170: 443-453.
40. Wang X, Lin G, Martins-Taylor K, Zeng H, Xu RH. Inhibition of caspase-mediated anoikis is critical for basic fibroblast growth factor-sustained culture of human pluripotent stem cells. J Biol Chem 2009; 284: 34054-34064.
41. Watanabe K, Ueno M, Kamiya D, Nishiyama A, Matsumura M, Wataya T et al. A rock inhibitor permits survival of dissociated human embryonic stem cells. Nat Biotechnol 2007; 25: 681-686.
42. Koyanagi M, Takahashi J, Arakawa Y, Doi D, Fukuda H, Hayashi H et al. Inhibition of the rho/rock pathway reduces apoptosis during transplantation of embryonic stem cell-derived neural precursors. J Neurosci Res 2008; 86: 270-280.
43. Braam SR, Nauw R, Ward-van Oostwaard D, Mummery C, Passier R. Inhibition of rock improves survival of human embryonic stem cell-derived cardiomyocytes after dissociation. Ann N Y Acad Sci 2010; 1188: 52-57.
44. Svoboda KK, Moessner P, Field T, Acevedo J. Rock inhibitor (y27632) increases apoptosis and disrupts the actin cortical mat in embryonic avian corneal epithelium. Dev Dyn 2004; 229: 579-590.
45. Moore M, Marroquin BA, Gugliotta W, Tse R, White SR. Rho kinase inhibition initiates apoptosis in human airway epithelial cells. Am J Respir Cell Mol Biol 2004; 30: 379-387.
46. Shi J,Wei L. Rho kinase in the regulation of cell death and survival. Arch Immunol Ther Exp (Warsz) 2007; 55: 61-75.
47. Chang J, Xie M, Shah VR, Schneider MD, Entman ML, Wei L et al. Activation of rho-associated coiled-coil protein kinase 1 (rock-1) by caspase-3 cleavage plays an essential role in cardiac myocyte apoptosis. Proc Natl Acad Sci USA 2006; 103: 14495-14500.
48. Shi J, Zhang YW, Yang Y, Zhang L, Wei L. Rock1 plays an essential role in the transition from cardiac hypertrophy to failure in mice. J Mol Cell Cardiol 2010; 49: 819-828.
49. Vemula S, Shi J, Mali RS, Ma P, Liu Y, Hanneman P et al. Rock1 functions as a critical regulator of stress erythropoiesis and survival by regulating p53. Blood 2012; 120: 2868-2878.
50. Mali RS, Ramdas B, Ma P, Shi J, Munugalavadla V, Sims E et al. Rho kinase regulates the survival and transformation of cells bearing oncogenic forms of kit, flt3, and bcr-abl. Cancer Cell 2011; 20: 357-369.
51. Yoneda A, Ushakov D, Multhaupt HA, Couchman Jr. Fibronectin matrix assembly requires distinct contributions from rho kinases i and -ii. Mol Biol Cell 2007; 18: 66-75.
52. Noguchi M, Hosoda K, Fujikura J, Fujimoto M, Iwakura H, Tomita T et al. Genetic and pharmacological inhibition of rho-associated kinase ii enhances adipogenesis. J Biol Chem 2007; 282: 29574-29583.
53. Wang Y, Zheng XR, Riddick N, Bryden M, Baur W, Zhang X et al. Rock isoform regulation of myosin phosphatase and contractility in vascular smooth muscle cells. Circ Res 2009; 104: 531-540.
54. Mong PY, Wang Q. Activation of rho kinase isoforms in lung endothelial cells during inflammation. J Immunol 2009; 182: 2385-2394.
55. Bryan BA, Dennstedt E, Mitchell DC, Walshe TE, Noma K, Loureiro R et al. Rhoa/rock signaling is essential for multiple aspects of vegf-mediated angiogenesis. Faseb J 2010; 24: 3186-3195.
56. Lock FE, Hotchin NA. Distinct roles for rock1 and rock2 in the regulation of keratinocyte differentiation. PLoS One 2009; 4: e8190.
57. Chun KH, Araki K, Jee Y, Lee DH, Oh BC, Huang H et al. Regulation of glucose transport by rock1 differs from that of rock2 and is controlled by actin polymerization. Endocrinology 2012; 153: 1649-1662.
58. Darenfed H, Dayanandan B, Zhang T, Hsieh SH, Fournier AE, Mandato CA. Molecular characterization of the effects of y-27632. Cell Motil Cytoskeleton 2007; 64: 97-109.
59. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 1983; 65: 55-63.